\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Address Baird William	1 0	on*	2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC</u> [FOLD]		tionship of Reporting Pers all applicable) Director	son(s) to Issuer 10% Owner
(Last) 1 CEDAR BROC	(First) DK DRIVE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/20/2015	х	Officer (give title below) Chief Financial	Other (specify below)
(Street) CRANBURY (City)	NJ (State)	08512 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More thar Person	orting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(insu. 4)
Common stock	03/20/2015		M ⁽¹⁾		5,080	A	\$11.506 ⁽²⁾	105,080	D	
Common stock	03/20/2015		M ⁽¹⁾		2,655	A	\$11.506(2)	107,735	D	
Common stock	03/20/2015		M ⁽¹⁾		7,500	A	\$11.506 ⁽²⁾	115,235	D	
Common stock	03/20/2015		S ⁽¹⁾		15,235	D	\$11.506 ⁽³⁾	100,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	oosed 0) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$3.53	03/20/2015		M ⁽¹⁾			5,080	01/28/2014	01/28/2023	Common Stock	5,080	\$0.00	48,420	D	
Stock Options (right to buy)	\$2.52	03/20/2015		M ⁽¹⁾			2,655	06/18/2014	06/18/2023	Common stock	2,655	\$0.00	51,534	D	
Stock options (right to buy)	\$2.45	03/20/2015		M ⁽¹⁾			7,500	01/03/2015	01/03/2024	Common stock	7,500	\$0.00	82,500	D	

Explanation of Responses:

1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.

2. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.17 to \$11.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. 3. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.17 to \$11.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. **Remarks:**

> <u>/s/ William D. Baird, III</u> ** Signature of Reporting Person

<u>03/24/2015</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.